NEW BRUNSWICK, N.J. / Feb 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5th, at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time).
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48-hrs after the webcast.
| Last Trade: | US$145.58 |
| Daily Change: | -0.27 -0.19 |
| Daily Volume: | 4,233,700 |
| Market Cap: | US$350.850B |
December 09, 2024 December 08, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
